Keywords: muse, sales, up, vivus, says, net, alprostadil
MUSE sales on the up at Vivus
Article | 25 March 2002
Vivus says that US net sales of MUSE (alprostadil), its treatment forerectile dysfunction, increased 26.5% for the three-month period from December 2001 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
